Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Top Ten Searches
etanercept hypertension chf antiphospholipid fibrosis mrsa scid renal cell rickets counterpulsationYour Article Summary
See Latest ArticlesEfficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease
The American Journal of Cardiology, 11/24/08
Conard SE et al. – Addition of ezetimibe 10 mg to atorvastatin 20 mg is generally well tolerated with significantly greater lipid-lowering efficacy compared with doubling atorvastatin to 40 mg in hypercholesterolemia pts at moderately high risk for coronary heart disease.
Methods- Study of efficacy and safety of ezetimibe 10 mg added to atorvastatin 20 mg compared with doubling atorvastatin to 40 mg in hypercholesterolemia pts at moderately high risk for coronary heart disease who did not reach low-density lipoprotein (LDL) cholesterol levels <100 mg/dl with atorvastatin 20 mg
- Double-blind, randomized, parallel-group, multicenter 6-wk trial of 196 pts treated with atorvastatin 20 mg
- Administration of atorvastatin 20 mg plus ezetimibe 10 mg or atorvastatin 40 mg for 6 wks
- Significantly greater reductions in LDL cholesterol with ezetimibe plus atorvastatin vs increased atorvastatin (-31% vs -11%)
- Significantly greater reductions in non-high-density lipoprotein cholesterol, total cholesterol, and apolipoprotein B with ezetimibe plus atorvastatin
- Significantly more pts reached LDL cholesterol levels <100 mg/dL with ezetimibe plus atorvastatin vs increased atorvastatin (84% vs 49%)
- Comparable results between treatment groups for high-density lipoprotein cholesterol, triglycerides, apolipoprotein A-I, and high-sensitivity C-reactive protein
- Incidences of clinical and laboratory adverse experiences generally similar between groups
Today in Atherosclerosis/Lipids...keeping you current
Receive free subspecialty "5-minute updates" via email
Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study)
The American Journal of Cardiology, 06/22/09
Residual cardiovascular risk in treated hypertension and hyperlipidaemia: The PRIME Study
Journal of Human Hypertension, 06/03/09
Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid sub-study
Breast Cancer Research, 06/18/09
Sponsor
Article Search
Sponsor